Blinatumomab Consolidation in Real World
NCT07117136 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2025-11-12
Summary
This will be a multi-center registry for patients with B-ALL. Patient data will be collected both retrospectively and prospectively. The data forms and surveys will be built and managed through REDCap, a secure web application managed by the Clinical \& Translational Science Institute.
Conditions
- B-Cell Acute Lymphoblastic Leukaemia
Sponsors & Collaborators
-
Medical College of Wisconsin
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2025-08-28
- Primary Completion
- 2029-05-14
- Completion
- 2029-05-14
Countries
- United States
Study Locations
More Related Trials
-
Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and/or BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)
NCT07178912 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT01466179 ·Status: COMPLETED ·Phase: PHASE2
-
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT04506086 ·Status: TERMINATED ·Phase: PHASE4
-
Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
NCT06507514 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
NCT07153796 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Blinatumomab Bridging Therapy for BALL
NCT04556084 ·Status: TERMINATED ·Phase: PHASE2
-
A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia
NCT07223190 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia
NCT02143414 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Reduced-dose Chemotherapy Followed by Blinatumomab in Induction Therapy of Newly Diagnosed Non-elderly Ph-B-ALL
NCT05557110 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Inotuzumab and Blinatumomab in People With B-cell Acute Lymphoblastic Leukemia
NCT07313852 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
NCT03914625 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
NCT02187354 ·Status: NO_LONGER_AVAILABLE
-
Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic Leukemia
NCT03709719 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL
NCT07301424 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia
NCT07192237 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)
NCT06649006 ·Status: COMPLETED ·Phase: PHASE1
-
Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
NCT04044560 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
NCT03114865 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.
NCT03541083 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)
NCT00560794 ·Status: COMPLETED ·Phase: PHASE2
-
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
NCT05837689 ·Status: UNKNOWN
-
Blinatumomab Maintenance After Allo-HSCT
NCT06438796 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
NCT04521231 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Blinatumomab Plus Reduced-dose Chemotherapy in Treating B-ALL
NCT06742515 ·Status: RECRUITING ·Phase: PHASE2
-
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
NCT02101853 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3